Evidence map›Paper›PMID 39754001›Full record

ReviewNeurology and therapy2025

Serum Biomarkers in Transthyretin Amyloidosis: An Overview of Neurofilaments, Cardiac, Renal, and Gastrointestinal Involvement.

Valeria Guglielmino, Francesca Vitali, Angela Romano, Guido Primiano, Maria Ausilia Sciarrone, Marco Luigetti

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Valeria GuglielminoDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesca VitaliDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Angela RomanoUOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Guido PrimianoDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Maria Ausilia SciarroneDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Marco LuigettiDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy. mluigetti@gmail.com.ORCID http://orcid.org/0000-0001-7539-505X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary transthyretin amyloidosis (ATTRv, v for variant) is a genetic disorder characterized by the deposition of misfolded transthyretin (TTR) protein in tissues, resulting in progressive dysfunction of multiple organs, including the nervous system, heart, kidneys, and gastrointestinal (GI) tract. Noninvasive serum biomarkers have become key tools for diagnosing and monitoring ATTRv. This review examines the role of available biomarkers for neurological, cardiac, renal, gastrointestinal, and multisystemic involvement in ATTRv. A thorough understanding of these biomarkers is essential for effective disease management and therapeutic monitoring.

Indexed as

BiomarkersCardiac amyloidosisDisease progression monitoringEarly diagnosisMultisystemic diseaseNeurofilament light chainPolyneuropathyTherapeutic responseTransthyretin amyloidosis

Identifiers

PMID39754001
PMCPMC11762045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.